APA (7th ed.) Citation

Brahmi, M., Tredan, O., Gomez-Roca, C., Italiano, A., Saada, E., Bertucci, F., . . . Dufresne, A. (2024). LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST "Ribociclib/HDM201" basket study. Annals of Oncology, 35, S1266. https://doi.org/10.1016/j.annonc.2024.08.2323

Chicago Style (17th ed.) Citation

Brahmi, M., et al. "LBA80 Siremadlin (S) and Ribociclib (R) in Patients (pt) with Advanced Well-differentiated/dedifferentiated Liposarcomas (WD/DD LPS) and Other Molecularly Selected Cancers: Final Analysis of the MEGAMOST "Ribociclib/HDM201" Basket Study." Annals of Oncology 35 (2024): S1266. https://doi.org/10.1016/j.annonc.2024.08.2323.

MLA (9th ed.) Citation

Brahmi, M., et al. "LBA80 Siremadlin (S) and Ribociclib (R) in Patients (pt) with Advanced Well-differentiated/dedifferentiated Liposarcomas (WD/DD LPS) and Other Molecularly Selected Cancers: Final Analysis of the MEGAMOST "Ribociclib/HDM201" Basket Study." Annals of Oncology, vol. 35, 2024, p. S1266, https://doi.org/10.1016/j.annonc.2024.08.2323.